NCT01779505View on ClinicalTrials.gov

A Phase 1a Trial Assessing the Safety, Tolerability, and Immunogenicity of GS-4774 (GI-13020) at Various Dose Levels and Regimens in Healthy Adults

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 31, 2013

Primary Completion Date

August 31, 2013

Study Completion Date

August 31, 2013

Conditions

Healthy Volunteers

Interventions

BIOLOGICAL

GS-4774

GS-4774 is a recombinant yeast-based biological product engineered to express HBV antigens. The product is a heat-killed yeast (S. cerevisiae) containing a chimera of HBV X, Score, and Core antigens.

Trial Locations (1)

85283

Celerion, Phoenix